ReviewJournal of hematology & oncology2015

AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy.

Jingjing Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.